| Aug 6 |
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
|
| Aug 4 |
Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results
|
| Aug 3 |
Agios Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
|
| Aug 2 |
Agios' Pyrukynd misses primary endpoint in phase 3 pediatric rare blood disorder trial
|
| Aug 2 |
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
|
| Aug 2 |
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12%
|
| Aug 1 |
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides
|
| Aug 1 |
Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 1 |
Agios Pharmaceuticals GAAP EPS of -$1.69 misses by $0.09, revenue of $8.62M misses by $0.69M
|
